Fever-Tree reported an 8% increase in adjusted brand revenue to £183.6 million for the first half of 2026, while adjusted EBITDA rose 9% to £20.1 million. US revenue grew 11% at constant currency, supported by expanded distribution and marketing. Jefferies retained its buy rating and 1,100p price target, citing stronger US growth and improved earnings prospects.